Ekso Bionics (NASDAQ:EKSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report released on Sunday morning. The firm issued a hold rating on the stock.

Several other brokerages also recently commented on EKSO. HC Wainwright cut their price objective on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th. Lake Street Capital reduced their price target on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a research note on Tuesday, October 29th.

Ekso Bionics Price Performance

EKSO stock opened at $0.65 on Friday. The stock has a market cap of $14.28 million, a PE ratio of -1.00 and a beta of 1.43. Ekso Bionics has a 12 month low of $0.50 and a 12 month high of $3.13. The company has a 50-day moving average price of $0.76 and a 200 day moving average price of $0.99. The company has a current ratio of 2.81, a quick ratio of 2.14 and a debt-to-equity ratio of 0.28.

Ekso Bionics (NASDAQ:EKSO) last announced its earnings results on Monday, October 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.02). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The business had revenue of $4.13 million for the quarter, compared to analysts’ expectations of $6.00 million. During the same quarter last year, the firm earned ($0.24) EPS. Equities research analysts anticipate that Ekso Bionics will post -0.48 earnings per share for the current year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.